---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-001611"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2023-02-08T23:59:59+00:00"
generated_at: "2026-06-19T21:49:51.971421+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viking Q4 net loss $0.26/shr; cash $155M; NASH study data expected Q2 2023

## Summary
- Net loss $19.6M ($0.26/shr) for Q4 2022 vs $12.4M ($0.16/shr) in Q4 2021; R&D expense rose to $16.2M.
- Full-year 2022 net loss $68.9M ($0.90/shr) vs $55.0M ($0.71/shr) in 2021; cash $155M (down from $202M).
- Enrollment completed for Phase 2b VOYAGE study of VK2809 in NASH/fibrosis; topline data expected Q2 2023.
- Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; initial data expected Q1 2023.
- Phase 1b study of VK0214 in X-ALD enrolling; data expected H2 2023; cash runway beyond key milestones.

## SEC filing metadata
- accession: 0001564590-23-001611
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2023-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000156459023001611/0001564590-23-001611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000156459023001611/vktx-8k_20230208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-001611
- JSON: https://secwatch.observer/filing/0001564590-23-001611.json
- Plain text: https://secwatch.observer/filing/0001564590-23-001611.txt

## Key facts
- Earnings Releases
  Viking Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2022.
  - Period: fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 8, 2023, we issued a press release reporting our financial results for the fourth quarter and year ended December 31, 2022 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000156459023001611/0001564590-23-001611-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.